Clinical trials: Early Rheumatoid Arthritis
- Condition Early Rheumatoid Arthritis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Rheumatoid Arthritis
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
The study aims to evaluate the predictability of early response to Certolizumab pegol in combination with Methotrexate at one year in patients with moderate to severe rheumatoid arthritis.
- Trial name
- SPEED (NCT01443364)
- Testing
- Certolizumab pegol
- Where
- 18 sites in Italy
- Volunteers
- 132 people
- Sponsor
- UCB Italy s.p.a.
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis
This randomized, open-label, parallel-group study will assess the effect on disease remission of RoActemra/Actemra (tocilizumab) in combination with disease-modifying antirheumatic drugs (DMARDs) versus current best practice…
- Trial name
- NCT01251120
- Testing
- tocilizumab [RoActemra/Actemra], DMARD
- Where
- 6 sites in Finland
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis
To compare the effects of the combination of ETN and MTX to MTX alone on radiographic change and clinical disease activity in subjects with early RA over 12 months.
- Trial name
- NCT00195494
- Testing
- Etanercept, Methotrexate
- Where
- United States
- Volunteers
- 542 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
Good EULAR Response In Patients With Early Rheumatoid Arthritis
This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal…
- Trial name
- EARLY RA (NCT01558089)
- Testing
- etanercept, methotrexate
- Where
- 9 sites in Greece
- Volunteers
- 76 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis
The purpose of this exploratory sub-study was to evaluate from a clinical perspective the impact on disease activity of lowering the dose of abatacept from 10 mg/kg to 5 mg/kg in subjects who had achieved remission (Disease…
- Trial name
- NCT00989235
- Testing
- Abatacept
- Volunteers
- 108 people
- Sponsor
- Bristol-Myers Squibb
Arthritis Rheumatoid
This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.
This study is to investigate the effect of etanercept in early versus delayed referral for management of rheumatoid arthritis patients assessing real-world patient data entered in the Iraq National Center of Rheumatology database…
- Trial name
- NCT04267614
- Testing
- Etanercept
- Where
- Iraq
- Volunteers
- 1,226 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
This multicenter, open-label, single arm long-term extension of study WA19926 will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with early, moderate to severe rheumatoid arthritis who have…
- Trial name
- NCT01665430
- Testing
- Tocilizumab
- Where
- 4 sites in Poland
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Early Rheumatoid Arthritis
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy…
- Trial name
- PREMIER (NCT00195663)
- Testing
- Adalimumab, Methotrexate
- Where
- 123 sites in United States, Australia and 17 more
- Volunteers
- 799 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis.
- Trial name
- NCT01649804
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Hungary
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an…
- Trial name
- NCT04909801
- Testing
- Abatacept, Adalimumab, Methotrexate
- Where
- 75 sites in United States, Argentina and 12 more
- Volunteers
- 338 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 [NCT01519791].
- Trial name
- C-early (NCT01521923)
- Testing
- Certolizumab Pegol + Methotrexate (MTX)
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 359 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis
The purpose of this study is to examine changes in immune cells and proteins in response to treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus adalimumab, both given in combination with…
- Trial name
- NCT02557100
- Testing
- Abatacept, Adalimumab, Methotrexate
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA)…
- Trial name
- TELLUS (NCT02393378)
- Testing
- Namilumab, Adalimumab, Methotrexate
- Where
- 13 sites in Czechia, Estonia and 3 more
- Volunteers
- 7 people
- Sponsor
- Takeda
Rheumatoid Arthritis
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission…
- Trial name
- NCT01142726
- Testing
- Abatacept, Methotrexate
- Where
- 73 sites in United States, Australia and 13 more
- Volunteers
- 511 people
- Sponsor
- Bristol-Myers Squibb
Arthritis Rheumatoid
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.
- Trial name
- NCT04721821
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 7,807 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis…
- Trial name
- BEGIN (NCT04004429)
- Testing
- 50 mg AP1189, AP1189
- Where
- 2 sites in Denmark, Norway
- Volunteers
- 105 people
- Sponsor
- SynAct Pharma Aps
Rheumatoid Arthritis
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Phase IIIb study to determine early response to Certolizumab Pegol (CZP) with Magnetic Resonance Imaging (MRI) score Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials (OMERACT) RA MRI Scoring System (RAMRIS) in…
- Trial name
- MARVELOUS (NCT01235598)
- Testing
- Certolizumab Pegol (CZP) 200 mg, Certolizumab Pegol (CZP) 400 mg
- Where
- 10 sites in Denmark, Netherlands and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)
Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve.
- Trial name
- NCT01164579
- Testing
- Tasocitinib plus Methotrexate
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
This randomized, double-blind, placebo-controlled study will compare the efficacy with regard to sustained remission and safety of tocilizumab and methotrexate, in combination or as monotherapy, in treatment-naïve patients with…
- Trial name
- NCT01034137
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 21 sites in Netherlands
- Volunteers
- 317 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced…
- Trial name
- RADAR (NCT01162421)
- Testing
- adalimumab, Methotrexate
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)